id	sid	eid	entity	type
gsrj-12	1	1	pharmacoresistance ariel le	ORG
gsrj-12	1	2	makenzie thomas	PERSON
gsrj-12	1	3	brady stallman	PERSON
gsrj-12	1	4	kathryn meadows	PERSON
gsrj-12	1	5	vidya bhargava	PERSON
gsrj-12	1	6	one	CARDINAL
gsrj-12	1	7	2021	CARDINAL
gsrj-12	1	8	georgetown scientific research	ORG
gsrj-12	1	9	99	CARDINAL
gsrj-12	1	10	georgetown scientific research journal	ORG
gsrj-12	1	11	pharmacoresistance ariel le	ORG
gsrj-12	1	12	makenzie thomas	PERSON
gsrj-12	1	13	brady stallman	PERSON
gsrj-12	1	14	kathryn meadows	PERSON
gsrj-12	1	15	vidya bhargava department of human science	ORG
gsrj-12	1	16	georgetown university school	ORG
gsrj-12	1	17	washington d.c.	GPE
gsrj-12	1	18	united states	GPE
gsrj-12	1	19	america e	GPE
gsrj-12	1	20	mst82@georgetown.edu	ORG
gsrj-12	2	1	aed	ORG
gsrj-12	7	1	tariquidar	PERSON
gsrj-12	8	1	pgp	ORG
gsrj-12	9	1	pharmacoresistance	PERSON
gsrj-12	11	1	pharmacoresistance	PERSON
gsrj-12	11	2	100	CARDINAL
gsrj-12	11	3	https://doi.org/10.48091/uwyg8998 1	DATE
gsrj-12	13	1	at least two	CARDINAL
gsrj-12	13	2	2.2 million	CARDINAL
gsrj-12	13	3	the united states	GPE
gsrj-12	13	4	over 65 million	CARDINAL
gsrj-12	14	1	0.5%	PERCENT
gsrj-12	14	2	years	DATE
gsrj-12	15	1	three	CARDINAL
gsrj-12	16	1	1	CARDINAL
gsrj-12	16	2	1,000	CARDINAL
gsrj-12	16	3	every year	DATE
gsrj-12	17	1	the united states	GPE
gsrj-12	17	2	over 150,000	CARDINAL
gsrj-12	17	3	annually	DATE
gsrj-12	17	4	one	CARDINAL
gsrj-12	17	5	26	CARDINAL
gsrj-12	18	1	annual	DATE
gsrj-12	18	2	the united states	GPE
gsrj-12	18	3	$9.6 billion	MONEY
gsrj-12	22	1	over one-third	CARDINAL
gsrj-12	22	2	aed	ORG
gsrj-12	22	3	two	CARDINAL
gsrj-12	23	1	about 50%	PERCENT
gsrj-12	23	2	first	ORDINAL
gsrj-12	23	3	aed	ORG
gsrj-12	23	4	13%	PERCENT
gsrj-12	23	5	second	ORDINAL
gsrj-12	23	6	aed	ORG
gsrj-12	23	7	20-25%	PERCENT
gsrj-12	23	8	aed	ORG
gsrj-12	24	1	abc	ORG
gsrj-12	24	2	three	CARDINAL
gsrj-12	24	3	abc	ORG
gsrj-12	24	4	101	CARDINAL
gsrj-12	24	5	abc	ORG
gsrj-12	24	6	abc	ORG
gsrj-12	26	1	2	CARDINAL
gsrj-12	27	1	2017	CARDINAL
gsrj-12	28	1	pharmacoresistance	PERSON
gsrj-12	29	1	one	CARDINAL
gsrj-12	30	1	abc	ORG
gsrj-12	30	2	aed	ORG
gsrj-12	33	1	2011	DATE
gsrj-12	33	2	bbb	ORG
gsrj-12	33	3	option.10	GPE
gsrj-12	33	4	102	CARDINAL
gsrj-12	34	1	3	CARDINAL
gsrj-12	34	2	about one-third	CARDINAL
gsrj-12	34	3	recent years	DATE
gsrj-12	34	4	one	CARDINAL
gsrj-12	34	5	abc	ORG
gsrj-12	34	6	mechanism.8,12	ORG
gsrj-12	34	7	aed	ORG
gsrj-12	34	8	bbb	ORG
gsrj-12	35	1	substances.12,13	PRODUCT
gsrj-12	37	1	bbb	ORG
gsrj-12	37	2	bbb	ORG
gsrj-12	37	3	brain.11,12	GPE
gsrj-12	38	1	one	CARDINAL
gsrj-12	39	1	aed	ORG
gsrj-12	39	2	25 days	DATE
gsrj-12	39	3	s aed	ORG
gsrj-12	41	1	aed	ORG
gsrj-12	42	1	aed	ORG
gsrj-12	43	1	bbb	ORG
gsrj-12	45	1	5	CARDINAL
gsrj-12	46	1	pgp	ORG
gsrj-12	47	1	aed	ORG
gsrj-12	48	1	the aed response	ORG
gsrj-12	50	1	one	CARDINAL
gsrj-12	50	2	10	CARDINAL
gsrj-12	50	3	aed	ORG
gsrj-12	50	4	10	CARDINAL
gsrj-12	50	5	103	CARDINAL
gsrj-12	51	1	10ohcbz	CARDINAL
gsrj-12	51	2	10	CARDINAL
gsrj-12	52	1	pgp	ORG
gsrj-12	52	2	10	CARDINAL
gsrj-12	52	3	bbb	ORG
gsrj-12	53	1	10	CARDINAL
gsrj-12	53	2	10	CARDINAL
gsrj-12	53	3	xr9576	GPE
gsrj-12	56	1	bbb	ORG
gsrj-12	57	1	van vliet et al.	PERSON
gsrj-12	57	2	pht	ORG
gsrj-12	57	3	aed	ORG
gsrj-12	57	4	pht	ORG
gsrj-12	57	5	pht	ORG
gsrj-12	58	1	pht	ORG
gsrj-12	59	1	aed	ORG
gsrj-12	59	2	aed	ORG
gsrj-12	59	3	pharmacoresistance	PERSON
gsrj-12	61	1	4	CARDINAL
gsrj-12	61	2	4.1	CARDINAL
gsrj-12	63	1	1	CARDINAL
gsrj-12	64	1	10	CARDINAL
gsrj-12	64	2	aed	ORG
gsrj-12	64	3	104	CARDINAL
gsrj-12	64	4	bbb	ORG
gsrj-12	64	5	1	CARDINAL
gsrj-12	65	1	aed	ORG
gsrj-12	65	2	1	CARDINAL
gsrj-12	65	3	1	CARDINAL
gsrj-12	65	4	first	ORDINAL
gsrj-12	65	5	second	ORDINAL
gsrj-12	65	6	abc	ORG
gsrj-12	65	7	third	ORDINAL
gsrj-12	65	8	105	CARDINAL
gsrj-12	65	9	three	CARDINAL
gsrj-12	65	10	pgp	ORG
gsrj-12	65	11	1	CARDINAL
gsrj-12	66	1	first	ORDINAL
gsrj-12	67	1	first	ORDINAL
gsrj-12	67	2	second	ORDINAL
gsrj-12	67	3	first	ORDINAL
gsrj-12	68	1	second	ORDINAL
gsrj-12	68	2	abc	ORG
gsrj-12	68	3	third	ORDINAL
gsrj-12	69	1	three	CARDINAL
gsrj-12	70	1	4.2 tariquidar	QUANTITY
gsrj-12	71	1	two	CARDINAL
gsrj-12	71	2	pgp	ORG
gsrj-12	73	1	van vliet	PERSON
gsrj-12	73	2	e. a. et al.	PERSON
gsrj-12	73	3	third	ORDINAL
gsrj-12	73	4	one	CARDINAL
gsrj-12	73	5	pgp	ORG
gsrj-12	75	1	atp hydrolyzing	PERSON
gsrj-12	76	1	one	CARDINAL
gsrj-12	76	2	one	CARDINAL
gsrj-12	76	3	atpase	NORP
gsrj-12	76	4	over 50%.18	CARDINAL
gsrj-12	77	1	aed	ORG
gsrj-12	77	2	van vliet	PERSON
gsrj-12	78	1	e. a. et al	PERSON
gsrj-12	78	2	pht	ORG
gsrj-12	79	1	coadministering pht	PERSON
gsrj-12	79	2	frequent daily	ORG
gsrj-12	80	1	pht	ORG
gsrj-12	80	2	an additional 8 hours	TIME
gsrj-12	80	3	pht	ORG
gsrj-12	81	1	106	CARDINAL
gsrj-12	82	1	pht	ORG
gsrj-12	82	2	day 13	DATE
gsrj-12	83	1	pht co-	ORG
gsrj-12	83	2	the first 3 days	DATE
gsrj-12	84	1	pht	ORG
gsrj-12	84	2	bbb	ORG
gsrj-12	86	1	second	ORDINAL
gsrj-12	86	2	pgp pharmacoresistance	ORG
gsrj-12	88	1	one	CARDINAL
gsrj-12	88	2	four	CARDINAL
gsrj-12	88	3	over 90%	PERCENT
gsrj-12	88	4	two	CARDINAL
gsrj-12	88	5	24%	PERCENT
gsrj-12	89	1	one	CARDINAL
gsrj-12	90	1	2.5 fold	CARDINAL
gsrj-12	90	2	aed	ORG
gsrj-12	90	3	bbb	ORG
gsrj-12	91	1	aed	ORG
gsrj-12	91	2	method.22	LOC
gsrj-12	91	3	aed	ORG
gsrj-12	92	1	aed	ORG
gsrj-12	92	2	three	CARDINAL
gsrj-12	95	1	one	CARDINAL
gsrj-12	95	2	4.3	CARDINAL
gsrj-12	98	1	van vliet e. a. et al	PERSON
gsrj-12	99	1	41%	PERCENT
gsrj-12	99	2	drug.23	ORG
gsrj-12	99	3	one	CARDINAL
gsrj-12	99	4	107	CARDINAL
gsrj-12	100	1	20 two	CARDINAL
gsrj-12	100	2	the first few days	DATE
gsrj-12	100	3	aed	ORG
gsrj-12	100	4	21	CARDINAL
gsrj-12	102	1	two	CARDINAL
gsrj-12	103	1	millions	CARDINAL
gsrj-12	107	1	pgp	ORG
gsrj-12	107	2	aed	ORG
gsrj-12	109	1	aed	ORG
gsrj-12	109	2	aed	ORG
gsrj-12	110	1	two	CARDINAL
gsrj-12	112	1	aed	ORG
gsrj-12	112	2	aed	ORG
gsrj-12	118	1	1	CARDINAL
gsrj-12	118	2	pwfsdpnf	GPE
gsrj-12	118	3	108	CARDINAL
gsrj-12	121	1	5, 2020	DATE
gsrj-12	122	1	december 15, 2020	DATE
gsrj-12	126	1	june 20, 2019	DATE
gsrj-12	127	1	december 15, 2020	DATE
gsrj-12	128	1	epilepsy	PERSON
gsrj-12	130	1	2015;5(9	CARDINAL
gsrj-12	131	1	wirrell e	PERSON
gsrj-12	133	1	https://www.epilepsy.com/learn/drugresistant-epilepsy	PERSON
gsrj-12	134	1	october 5, 2020	DATE
gsrj-12	135	1	december 15, 2020	DATE
gsrj-12	136	1	massaro m	PERSON
gsrj-12	136	2	rabinowicz a.	PERSON
gsrj-12	138	1	2004;26(1):44-46	DATE
gsrj-12	138	2	french	NORP
gsrj-12	141	1	2007;48(s1):3-7	DATE
gsrj-12	141	2	doi:10.1111	ORG
gsrj-12	141	3	1167.2007.00992.x	CARDINAL
gsrj-12	141	4	girardi e	PERSON
gsrj-12	141	5	vazquez s	PERSON
gsrj-12	141	6	d'giano c. abc	ORG
gsrj-12	143	1	2007;48(s5):140-149	CARDINAL
gsrj-12	144	1	doi:10.1111	ORG
gsrj-12	144	2	abc	ORG
gsrj-12	146	1	2015;43(5):889-893	CARDINAL
gsrj-12	147	1	hartz ams	PERSON
gsrj-12	147	2	bauer b. drugresistant epilepsy	PERSON
gsrj-12	149	1	schlichtiger j	PERSON
gsrj-12	149	2	m.s. a.	ORG
gsrj-12	152	1	september 2011	DATE
gsrj-12	154	1	sisodiya s. etiology	ORG
gsrj-12	156	1	2007;3(6):320-330	CARDINAL
gsrj-12	157	1	doi:10.1038	ORG
gsrj-12	157	2	w	GPE
gsrj-12	157	3	potschka h. blood-brain	PERSON
gsrj-12	159	1	volk ha	PERSON
gsrj-12	159	2	löscher w.	PERSON
gsrj-12	161	1	marchi n	PERSON
gsrj-12	161	2	guiso g	PERSON
gsrj-12	162	1	10,11dyhydro-10-hydroxy-5hdibenzo(b	DATE
gsrj-12	164	1	2005;46(10):1613-1619	CARDINAL
gsrj-12	165	1	doi:10.1111/j.15281167.2005.00265.x vliet eav	ORG
gsrj-12	165	2	schaik rv	GPE
gsrj-12	168	1	kmr	PERSON
gsrj-12	168	2	lakshmi pk	PERSON
gsrj-12	169	1	brazilian journal of pharmaceutical sciences	ORG
gsrj-12	170	1	2012;48(3):353-367	CARDINAL
gsrj-12	171	1	109	CARDINAL
gsrj-12	171	2	georgetown scientific research	ORG
gsrj-12	174	1	2013;7:27	CARDINAL
gsrj-12	176	1	weidner ld	PERSON
gsrj-12	176	2	fung kl	PERSON
gsrj-12	176	3	kannan p	PERSON
gsrj-12	177	1	tariquidar	PERSON
gsrj-12	179	1	2015;44(2):275282	CARDINAL
gsrj-12	180	1	vliet eav	PERSON
gsrj-12	180	2	schaik rv	GPE
gsrj-12	182	1	2006;47(4):672-680	CARDINAL
gsrj-12	183	1	doi:10.1111	ORG
gsrj-12	183	2	1167.2006.00496.x	CARDINAL
gsrj-12	183	3	brandt	PERSON
gsrj-12	183	4	bethmann k	PERSON
gsrj-12	183	5	löscher w.	PERSON
gsrj-12	185	1	2006;24(1):202	CARDINAL
gsrj-12	185	2	doi:10.1016/j.nbd.2006.06.014 bauer m	ORG
gsrj-12	187	1	2011;91(2):227-233	CARDINAL
gsrj-12	188	1	doi:10.1038	ORG
gsrj-12	188	2	ma	PERSON
gsrj-12	188	3	moore	PERSON
gsrj-12	188	4	mcauley jw	PERSON
gsrj-12	190	1	2004;38(10):1631-1634	DATE
gsrj-12	192	1	l	DATE
gsrj-12	192	2	wagner p	PERSON
gsrj-12	192	3	ibrahim n	PERSON
gsrj-12	194	1	2005;104(4):682-691	CARDINAL
gsrj-12	196	1	110	CARDINAL
gsrj-12	196	2	the united states	GPE
gsrj-12	196	3	covid-19	PERSON
gsrj-12	196	4	new mexico	GPE
gsrj-12	196	5	utah	GPE